FOLEY & LARDNER LLP

Erin Swinstead

Associate

eswinstead@foley.com

Washington, D.C.
202.295.4041

Dr. Erin Swinstead integrates her scientific background in molecular biology and her experience in patent counseling to assist clients, ranging from biotechnology startups to large pharmaceutical and diagnostic companies, in protecting their intellectual properties. Her experience in patent counseling includes meeting with inventors to discuss patent strategies, patent drafting and prosecution, freedom-to-operate analysis, patent validity and infringement analysis, due diligence, and litigation support.

Erin possesses patent counseling experience across a wide range of technologies, including CAR-T cell therapy technology, antibodies, vaccines, diagnostics, gene therapy, embryo development, hormone therapy, food products, and genetics in plant biology. She also has experience in design patent drafting and prosecution.

Before joining Foley, Erin gained experience in patent counseling at a global firm located in Washington, D.C., and was a postdoctoral fellow at the National Institutes of Health (NIH) and National Cancer Institute (NCI). Her scientific background is largely in the hormone-driven cancer space, such as breast and prostate cancer. During her time at the NIH, Erin investigated the collaborative interactions of activated transcription factors and steroid receptors, with a focus on the genomic consequences of these interactions. She utilized a number of techniques coupled with next-generation sequencing to assess chromatin reprogramming and transcriptional regulation, including ChIP-seq, ATAC-seq, DNaseI-seq, and RNA-seq. She published her findings in several research journals, including *Cell* (as first author), and was awarded a U.S. Department of Defense Breast Cancer Breakthrough Fellowship as Principal Investigator.

Community Involvement

- Speaker, Experimental Biology Conference, ASBMB, San Diego, CA, (2016)
- Speaker, CCR-FYI, Colloquium, MD, (2015)
- Writer/editor, LRBGE Connect Newsletter (2018-2019)
- Chair, NIH Chromatin-DECODE seminar series/NIH, Special Interest Group (2018-2019)

FOLEY & LARDNER LLP

Presentations and Publications

- Co-author, “Identification of a novel GR-ARID1a-P53BP1 protein complex involved in DNA damage repair and cell cycle regulation” *Oncogene* (December 9, 2022)
- Co-author, “Meta-analysis of Chromatin Programming by Steroid Receptors” *Cell Reports* (September 24, 2019)
- Co-author, “Chromatin reprogramming in breast cancer” *Endocrine-Related Cancer* (July, 2018)
- Co-author, “Transcription factor assisted loading and enhancer dynamics dictate the hepatic fasting response” *Genome Research* (December 28, 2016)
- Co-author, “Pioneer factors and ATP-dependent chromatin remodeling factors interact dynamically: A new perspective” *Bioessays* (September, 2016)
- Co-author, “Steroid Receptors Reprogram FoxA1 Occupancy through Dynamic Chromatin Transitions” *Cell* (April 21, 2016)
- Co-author, “Steroid receptor crosstalk in breast cancer cell” *University of Adelaide* (July, 2014)
- Co-author, “Molecular and structural basis of androgen receptor responses to dihydrotestosterone, medroxyprogesterone acetate and ?4-tibolone” *Molecular and Cellular Endocrinology* (February 15, 2014)

Practice Areas

- Chemical, Biotechnology & Pharmaceutical
- Intellectual Property

Education

- Georgetown University Law Center, Washington, D.C. (J.D., 2024)
- University of Adelaide, South Australia, Australia (Ph.D., 2014)
    - Molecular Biology
    - Dean’s Commendation of Doctoral Thesis Excellence
- University of Adelaide, South Australia, Australia (B.H.S., 2010)
    - First class honours
- University of South Australia, South Australia, Australia (B.L.M., 2008)
    - Student representative, Australia Institute of Medical Science (2007-2008)

Admissions

- U.S. Patent and Trademark Office
- Washington, D.C.